Anna Caroli1, Annapaola Prestia, Sara Wade, Kewei Chen, Napatkamon Ayutyanont, Susan M Landau, Cindee M Madison, Cathleen Haense, Karl Herholz, Eric M Reiman, William J Jagust, Giovanni B Frisoni. 1. *Medical Imaging Unit, Biomedical Engineering Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Bergamo †Laboratory of Epidemiology and Neuroimaging, IRCCS Fatebenefratelli, Brescia §Department of Decision Science, Bocconi University, Milan, Italy ‡Department of Engineering, University of Cambridge **Institute of Brain, Behaviour, and Mental Health University of Cambridge, Cambridge ∥Banner Alzheimer's Institute, Phoenix, AZ ¶Helen Wills Neuroscience Institute, University of California, Berkeley, CA #Hannover Medical School, Clinic for Nuclear Medicine, Hannover, Germany ††Departments of Internal Medicine and Psychiatry, University Hospitals and University of Geneva, Geneva, Switzerland.
Abstract
BACKGROUND: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). METHODS: Magnetic resonance imaging, F-18 fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. RESULTS: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. CONCLUSION: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
BACKGROUND: The aim of this study was to compare the performance and power of the best-established diagnostic biological markers as outcome measures for clinical trials in patients with mild cognitive impairment (MCI). METHODS: Magnetic resonance imaging, F-18fluorodeoxyglucose positron emission tomography markers, and Alzheimer's Disease Assessment Scale-cognitive subscale were compared in terms of effect size and statistical power over different follow-up periods in 2 MCI groups, selected from Alzheimer's Disease Neuroimaging Initiative data set based on cerebrospinal fluid (abnormal cerebrospinal fluid Aβ1-42 concentration-ABETA+) or magnetic resonance imaging evidence of Alzheimer disease (positivity to hippocampal atrophy-HIPPO+). Biomarkers progression was modeled through mixed effect models. Scaled slope was chosen as measure of effect size. Biomarkers power was estimated using simulation algorithms. RESULTS: Seventy-four ABETA+ and 51 HIPPO+ MCI patients were included in the study. Imaging biomarkers of neurodegeneration, especially MR measurements, showed highest performance. For all biomarkers and both MCI groups, power increased with increasing follow-up time, irrespective of biomarker assessment frequency. CONCLUSION: These findings provide information about biomarker enrichment and outcome measurements that could be employed to reduce MCI patient samples and treatment duration in future clinical trials.
Authors: Dominic Holland; James B Brewer; Donald J Hagler; Christine Fennema-Notestine; Christine Fenema-Notestine; Anders M Dale Journal: Proc Natl Acad Sci U S A Date: 2009-12-08 Impact factor: 11.205
Authors: Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski Journal: Ann Neurol Date: 2009-04 Impact factor: 10.422
Authors: W J P Henneman; J D Sluimer; J Barnes; W M van der Flier; I C Sluimer; N C Fox; P Scheltens; H Vrenken; F Barkhof Journal: Neurology Date: 2009-03-17 Impact factor: 9.910
Authors: Xue Hua; Derrek P Hibar; Christopher R K Ching; Christina P Boyle; Priya Rajagopalan; Boris A Gutman; Alex D Leow; Arthur W Toga; Clifford R Jack; Danielle Harvey; Michael W Weiner; Paul M Thompson Journal: Neuroimage Date: 2012-11-12 Impact factor: 6.556
Authors: Annapaola Prestia; Anna Caroli; Wiesje M van der Flier; Rik Ossenkoppele; Bart Van Berckel; Frederik Barkhof; Charlotte E Teunissen; Anders E Wall; Stephen F Carter; Michael Schöll; Il Han Choo; Agneta Nordberg; Philip Scheltens; Giovanni B Frisoni Journal: Neurology Date: 2013-02-06 Impact factor: 9.910
Authors: Clifford R Jack; Matt A Bernstein; Nick C Fox; Paul Thompson; Gene Alexander; Danielle Harvey; Bret Borowski; Paula J Britson; Jennifer L Whitwell; Chadwick Ward; Anders M Dale; Joel P Felmlee; Jeffrey L Gunter; Derek L G Hill; Ron Killiany; Norbert Schuff; Sabrina Fox-Bosetti; Chen Lin; Colin Studholme; Charles S DeCarli; Gunnar Krueger; Heidi A Ward; Gregory J Metzger; Katherine T Scott; Richard Mallozzi; Daniel Blezek; Joshua Levy; Josef P Debbins; Adam S Fleisher; Marilyn Albert; Robert Green; George Bartzokis; Gary Glover; John Mugler; Michael W Weiner Journal: J Magn Reson Imaging Date: 2008-04 Impact factor: 4.813
Authors: N Schuff; N Woerner; L Boreta; T Kornfield; L M Shaw; J Q Trojanowski; P M Thompson; C R Jack; M W Weiner Journal: Brain Date: 2009-02-27 Impact factor: 13.501
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Cristina Muscio; Pietro Tiraboschi; Ugo P Guerra; Carlo A Defanti; Giovanni B Frisoni Journal: Front Aging Neurosci Date: 2015-03-11 Impact factor: 5.750
Authors: Hiroko H Dodge; Jian Zhu; Nora C Mattek; Daniel Austin; Judith Kornfeld; Jeffrey A Kaye Journal: PLoS One Date: 2015-09-17 Impact factor: 3.240
Authors: Sandra Weintraub; Maria C Carrillo; Sarah Tomaszewski Farias; Terry E Goldberg; James A Hendrix; Judith Jaeger; David S Knopman; Jessica B Langbaum; Denise C Park; Michael T Ropacki; Sietske A M Sikkes; Kathleen A Welsh-Bohmer; Lisa J Bain; Robert Brashear; Kumar Budur; Ana Graf; Ferenc Martenyi; Marta Segardahl Storck; Christopher Randolph Journal: Alzheimers Dement (N Y) Date: 2018-02-13